A new study on mice published in Nature Neuroscience finds that fingolimod (Novartis brand name Gilenya) a first-in-class sphingosine-1-phosphate-receptor modulator currently used in treating persons with severe relapsing remitting MS, may also have therapeutic value in treating Post Traumatic Stress Disorder (PTSD). The Nature Neuroscience study is titled…
Gilenya
Recommended Posts
- New European patent covers all dosing regimens of experimental MS therapy
- My dysphagia from MS shows up during a difficult swallowing study
- Brain volume loss may not reflect disability in progressive MS
- Along with hardships, my MS diagnosis has been a journey of learning
- MS causing fewer deaths, less disability than in the past: Study